Dragica Paunovic

Showing 1-6 of 6 articles

Author Bernard Chevalier

Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial

Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P

September 22, 2015 | 10.4244/EIJY14M12_13

Author Gian Battista Danzi

Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: the NOBORI 2 study

Danzi G, Chevalier B, Urban P, Fath-Ordoubadi F, Carrié D, Wiemer M, Serra A, Wijns W, Kala P, Stabile A, Ruigomez J, Sagic D, Laanmets P, Strupp G, West N, Paunovic D

May 15, 2012 | 10.4244/EIJV8I1A17

Author K Schulte

MISAGO 1: first-in-man clinical trial with Misago™ nitinol stent

Schulte K, Müller-Hülsbeck S, Cao P, Becquemin J, Langhoff R, Charalambous N, Desgranges P, Kobeiter H, Midulla M, Borovicanin V, Paunovic D, Beregi J

January 15, 2010

Author Miodrag Ostojic

First clinical comparison of Nobori –Biolimus A9 eluting stents with Cypher– Sirolimus eluting stents: NOBORI CORE nine months angiographic and one year clinical outcomes

Ostojic M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N, Nedeljkovic M, Mangovski L, Milosavljevic B, Stojkovic S, Orlic D, Antonic Z, Miloradovic V, Topic D, Paunovic D

March 20, 2008

Author Didier Blanchard

A novel ultra-thin bare metal stent (BMS): results from a worldwide registry

Blanchard D, Danzi G, Urban P, Moseri M, Juergens C, Guyon P, Nowak B, Tresukosol D, Suttorp MJ, Farshid A, Kornowski R, Garcia E, Yeend R, Nagai H, Paunovic D

August 20, 2007

Author Bernard Chevalier

Randomised comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial

Chevalier B, Serruys P, Silber S, Garcia E, Suryapranata H, Hauptmann K-E, Wijns W, Schuler G, Fath-Ordoubadi F, Worthley S, Thuesen L, Meredith I, Bressers M, Nagai H, Paunovic D

February 20, 2007

1

Latest news

Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue

(Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right))

December 6, 2019

The challenge of innovation for the (interventional?) cardiology world

December 6, 2019

This week's JAA's: EXTREME Study, Stent Optimization, Trifurcation disease and more

December 3, 2019

New update! Discover 17 new trials

(The Trials book is supported by Biotronik)

October 29, 2019

Guidance Papers

Guidelines, consensus & position papers

2019 – A leap year for valvular heart disease

(Course directors PCR London Valves 2019)

November 15, 2019

Last week's JAA's: DYNAMIC Trial, S3U registry and much more

November 26, 2019

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke